S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.86 (+2.77%)
AAPL   168.96 (+2.45%)
MSFT   288.94 (+2.35%)
META   178.38 (+5.84%)
GOOGL   119.54 (+2.50%)
AMZN   142.58 (+3.45%)
TSLA   882.01 (+3.77%)
NVDA   180.82 (+5.83%)
NIO   20.03 (+4.49%)
BABA   92.45 (+1.38%)
AMD   99.03 (+3.65%)
MU   61.37 (+3.75%)
T   18.01 (-0.50%)
CGC   3.28 (+14.29%)
GE   77.10 (+2.90%)
F   15.50 (+2.04%)
DIS   112.27 (+3.83%)
AMC   23.67 (+5.43%)
PYPL   98.93 (+4.71%)
PFE   49.90 (+0.24%)
NFLX   244.02 (+6.12%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.86 (+2.77%)
AAPL   168.96 (+2.45%)
MSFT   288.94 (+2.35%)
META   178.38 (+5.84%)
GOOGL   119.54 (+2.50%)
AMZN   142.58 (+3.45%)
TSLA   882.01 (+3.77%)
NVDA   180.82 (+5.83%)
NIO   20.03 (+4.49%)
BABA   92.45 (+1.38%)
AMD   99.03 (+3.65%)
MU   61.37 (+3.75%)
T   18.01 (-0.50%)
CGC   3.28 (+14.29%)
GE   77.10 (+2.90%)
F   15.50 (+2.04%)
DIS   112.27 (+3.83%)
AMC   23.67 (+5.43%)
PYPL   98.93 (+4.71%)
PFE   49.90 (+0.24%)
NFLX   244.02 (+6.12%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.86 (+2.77%)
AAPL   168.96 (+2.45%)
MSFT   288.94 (+2.35%)
META   178.38 (+5.84%)
GOOGL   119.54 (+2.50%)
AMZN   142.58 (+3.45%)
TSLA   882.01 (+3.77%)
NVDA   180.82 (+5.83%)
NIO   20.03 (+4.49%)
BABA   92.45 (+1.38%)
AMD   99.03 (+3.65%)
MU   61.37 (+3.75%)
T   18.01 (-0.50%)
CGC   3.28 (+14.29%)
GE   77.10 (+2.90%)
F   15.50 (+2.04%)
DIS   112.27 (+3.83%)
AMC   23.67 (+5.43%)
PYPL   98.93 (+4.71%)
PFE   49.90 (+0.24%)
NFLX   244.02 (+6.12%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.86 (+2.77%)
AAPL   168.96 (+2.45%)
MSFT   288.94 (+2.35%)
META   178.38 (+5.84%)
GOOGL   119.54 (+2.50%)
AMZN   142.58 (+3.45%)
TSLA   882.01 (+3.77%)
NVDA   180.82 (+5.83%)
NIO   20.03 (+4.49%)
BABA   92.45 (+1.38%)
AMD   99.03 (+3.65%)
MU   61.37 (+3.75%)
T   18.01 (-0.50%)
CGC   3.28 (+14.29%)
GE   77.10 (+2.90%)
F   15.50 (+2.04%)
DIS   112.27 (+3.83%)
AMC   23.67 (+5.43%)
PYPL   98.93 (+4.71%)
PFE   49.90 (+0.24%)
NFLX   244.02 (+6.12%)
NASDAQ:NVIV

InVivo Therapeutics - NVIV Stock Forecast, Price & News

$7.57
-0.88 (-10.41%)
(As of 08/10/2022 03:14 PM ET)
Add
Compare
Today's Range
$7.57
$8.10
50-Day Range
$3.75
$8.96
52-Week Range
$3.50
$20.23
Volume
1,300 shs
Average Volume
300,600 shs
Market Capitalization
$10.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NVIV stock logo

About InVivo Therapeutics (NASDAQ:NVIV) Stock

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on InVivo Therapeutics in a research note on Tuesday. They issued a "sell" rating on the stock.

InVivo Therapeutics Price Performance

InVivo Therapeutics stock traded down $0.18 during trading hours on Tuesday, reaching $8.45. The company had a trading volume of 211,165 shares, compared to its average volume of 300,600. The company has a 50-day moving average price of $4.49 and a 200 day moving average price of $6.28. The firm has a market cap of $11.75 million, a price-to-earnings ratio of -1.10 and a beta of 1.30. InVivo Therapeutics has a 12-month low of $3.50 and a 12-month high of $20.23.

InVivo Therapeutics (NASDAQ:NVIV - Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($1.94) EPS for the quarter.

Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVIV Stock News Headlines

Why InVivo Therapeutics Stock Falling?
InVivo Therapeutics Holdings(NVIV)
See More Headlines
Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVIV Company Calendar

Last Earnings
5/13/2020
Today
8/10/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVIV
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Net Income
$-9,900,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$13.22 per share

Miscellaneous

Free Float
1,390,000
Market Cap
$10.53 million
Optionable
Not Optionable
Beta
1.30

Key Executives

  • Dr. Richard M. Toselli (Age 64)
    Pres, CEO, Chief Medical Officer & Director
    Comp: $940.27k
  • Mr. Richard C. Christopher (Age 52)
    CFO & Treasurer
    Comp: $628.2k
  • Dr. Robert S. Langer Jr. (Age 73)
    Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board
  • Dr. Joseph Philip Vacanti (Age 73)
    Co-Founder
  • Mr. Jerome Gangitano
    Sr. VP of Operations
  • Ms. Heather Hamel
    VP of Legal Affairs & Bus. Devel. and Corp. Sec.
  • Dr. Louis Vaickus FACP (Age 69)
    M.D., Consultant













NVIV Stock - Frequently Asked Questions

How have NVIV shares performed in 2022?

InVivo Therapeutics' stock was trading at $11.4025 at the beginning of the year. Since then, NVIV stock has decreased by 31.2% and is now trading at $7.84.
View the best growth stocks for 2022 here
.

When is InVivo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our NVIV earnings forecast
.

How were InVivo Therapeutics' earnings last quarter?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) posted its earnings results on Wednesday, May, 13th. The biotechnology company reported ($61.75) earnings per share (EPS) for the quarter.

When did InVivo Therapeutics' stock split?

Shares of InVivo Therapeutics reverse split on the morning of Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of InVivo Therapeutics own?

What is InVivo Therapeutics' stock symbol?

InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

How do I buy shares of InVivo Therapeutics?

Shares of NVIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InVivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $7.84.

How much money does InVivo Therapeutics make?

InVivo Therapeutics (NASDAQ:NVIV) has a market capitalization of $10.91 million. The biotechnology company earns $-9,900,000.00 in net income (profit) each year or ($7.69) on an earnings per share basis.

How can I contact InVivo Therapeutics?

InVivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The official website for the company is www.invivotherapeutics.com. The biotechnology company can be reached via phone at (617) 863-5500 or via email at info@invivotherapeutics.com.

This page (NASDAQ:NVIV) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.